Navigation Links
New protein target may advance design of HIV and cancer drugs

Using small molecules containing platinum, Virginia Commonwealth University Massey Cancer Center researchers have created a process to inhibit a class of proteins important in HIV and cancer.

The findings may help researchers develop new drugs to fight HIV or cancer by selectively targeting proteins known as zinc fingers.

In the May 30 issue of the journal Chemistry & Biology, researchers reported that a zinc finger protein, known as HIV NCp7, can be inhibited when it is exposed to a platinum complex. They observed that when the HIV NCp7 protein interacts with platinum, the zinc portion of the molecule is ejected from the protein chain. This causes the protein to lose its tertiary structure or overall shape. For these molecules, shape is an important property that enables the protein to carry out certain biological functions.

The process, active site displacement, involved design of a platinum drug with higher affinity for the protein peptide backbone, thus eliminating the zinc from its active site.

In the specific case discussed in the paper, the HIV NCp7 protein is responsible for the proliferation of the HIV virus. If researchers can inhibit the action of this zinc finger protein, they can stop the spread of the virus.

"When we target specific viruses with drugs, over time patients can become resistant to treatment and the drug becomes ineffective. Therefore, novel biological processes and proteins are attractive targets for antiviral drug development," said lead author Nicholas Farrell, Ph.D., professor and chair in the Department of Chemistry at VCU and a member scientist with the VCU Massey Cancer Center.

According to Farrell, these study findings may also one day be applied to the selective targeting of zinc fingers involved in the biological processes responsible for the spread of cancer. By applying the concept to development of anticancer drugs, the researchers hope to design more specific clinical agen ts with reduced side effects compared to the very useful, but toxic, cisplatin and congeners.


'"/>

Source:Virginia Commonwealth University


Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: